Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy

Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy

The ability to genetically engineer oncolytic viruses in order to minimize side effects and improve the selective targeting of tumor cells has opened up novel opportunities for treating cancer. Understanding the mechanisms involved and the complex interaction between the viruses and the immune syste...

Full description

Saved in:
Bibliographic Details
Superior document:Frontiers Research Topics
:
Benjamin Gesundheit
Joshua P. Rosenzweig
Year of Publication:2017
Language:English
Series:Frontiers Research Topics
Physical Description:1 electronic resource (193 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993543719004498
ctrlnum (CKB)4100000002484765
(oapen)https://directory.doabooks.org/handle/20.500.12854/55224
(EXLCZ)994100000002484765
collection bib_alma
record_format marc
spelling Benjamin Gesundheit auth
Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy
Frontiers Media SA 2017
1 electronic resource (193 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Frontiers Research Topics
The ability to genetically engineer oncolytic viruses in order to minimize side effects and improve the selective targeting of tumor cells has opened up novel opportunities for treating cancer. Understanding the mechanisms involved and the complex interaction between the viruses and the immune system will undoubtedly help guide the development of new strategies. Theranostic biomarkers to monitor these therapies in clinical trials serve an important need in this innovative field and demand further research.
English
theranostic nanomedicine
cancer immunotherapy
oncolytic viruses
antitumor immunity
oncoimmunology
gene expression
transgenes
2-88945-358-8
Joshua P. Rosenzweig auth
language English
format eBook
author Benjamin Gesundheit
spellingShingle Benjamin Gesundheit
Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy
Frontiers Research Topics
author_facet Benjamin Gesundheit
Joshua P. Rosenzweig
author_variant b g bg
author2 Joshua P. Rosenzweig
author2_variant j p r jpr
author_sort Benjamin Gesundheit
title Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy
title_full Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy
title_fullStr Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy
title_full_unstemmed Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy
title_auth Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy
title_new Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy
title_sort oncolytic viruses - genetically engineering the future of cancer therapy
series Frontiers Research Topics
series2 Frontiers Research Topics
publisher Frontiers Media SA
publishDate 2017
physical 1 electronic resource (193 p.)
isbn 2-88945-358-8
illustrated Not Illustrated
work_keys_str_mv AT benjamingesundheit oncolyticvirusesgeneticallyengineeringthefutureofcancertherapy
AT joshuaprosenzweig oncolyticvirusesgeneticallyengineeringthefutureofcancertherapy
status_str n
ids_txt_mv (CKB)4100000002484765
(oapen)https://directory.doabooks.org/handle/20.500.12854/55224
(EXLCZ)994100000002484765
carrierType_str_mv cr
hierarchy_parent_title Frontiers Research Topics
is_hierarchy_title Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy
container_title Frontiers Research Topics
author2_original_writing_str_mv noLinkedField
_version_ 1787548900015472640
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01603nam-a2200361z--4500</leader><controlfield tag="001">993543719004498</controlfield><controlfield tag="005">20231214133235.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2017 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000002484765</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/55224</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000002484765</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Benjamin Gesundheit</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oncolytic Viruses - Genetically Engineering the Future of Cancer Therapy</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (193 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The ability to genetically engineer oncolytic viruses in order to minimize side effects and improve the selective targeting of tumor cells has opened up novel opportunities for treating cancer. Understanding the mechanisms involved and the complex interaction between the viruses and the immune system will undoubtedly help guide the development of new strategies. Theranostic biomarkers to monitor these therapies in clinical trials serve an important need in this innovative field and demand further research.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">theranostic nanomedicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncolytic viruses</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antitumor immunity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oncoimmunology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transgenes</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-358-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Joshua P. Rosenzweig</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:47:27 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2018-03-10 17:16:05 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5337428260004498&amp;Force_direct=true</subfield><subfield code="Z">5337428260004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337428260004498</subfield></datafield></record></collection>

Similar Items